Vertex Pharmaceuticals is buying Crinetics Pharmaceuticals in a roughly $10 billion deal, giving Vertex a bigger position in rare endocrine diseases and a new growth path beyond cystic fibrosis.

For traders, this is more than one biotech takeover. It signals that profitable drugmakers are still willing to pay large premiums for rare disease companies with approved products, late-stage pipelines and focused specialist markets.

Crinetics is the clear deal winner. Vertex may be judged more carefully because buyers must prove that a large premium can create long-term value.

Winners

Rare disease biotech takeover candidates

This group can benefit because the deal highlights the value of rare disease assets. Companies with approved drugs, late-stage clinical data, defined patient populations and specialist markets ma ...